Hematologic Oncology | Specialty

Dr. D'Angelo on Novel Therapeutics Under Exploration in DLBCL

March 3rd 2021

Christopher R. D’Angelo, MD, discusses novel therapeutics under investigation in patients with diffuse large B-cell lymphoma.

Novel Combination Therapies Show Promise in Managing Early Relapse in Multiple Myeloma

March 2nd 2021

There is building evidence that novel combination therapies could be effective in treating early relapsed multiple myeloma.

Genotyping Offers Insights Into Key Characteristics of ALL Subtypes

March 2nd 2021

Genomic sequencing is a critical step in informing the prognosis of patients with acute lymphoblastic leukemia and more information regarding specific subgroups of ALL, such as lineage ambiguous ALL, could pave the way for more personalized therapies for patients.

Armand Reviews Novel Therapeutics in Relapsed/Refractory Follicular Lymphoma

March 2nd 2021

Although it is too soon to tell whether the addition of a CD20-directed antibody to novel agents in relapsed/refractory follicular lymphoma should become standard practice, it is clear that immunotherapy could represent the next paradigm shift.

Investigative Interventions Gain Ground in GVHD

March 2nd 2021

With an increased understanding of disease biology, several approaches are under examination to optimize the management of patients with graft-versus-host disease.

Zanubrutinib Approved in Canada for Waldenström Macroglobulinemia

March 2nd 2021

Health Canada has approved the BTK inhibitor zanubrutinib for the treatment of adult patients with Waldenström macroglobulinemia.

Next Steps in Mantle Cell Lymphoma

March 2nd 2021

MRD Assessment in Mantle Cell Lymphoma

March 2nd 2021

Novel Therapies in the Pipeline in Mantle Cell Lymphoma

March 2nd 2021

Dr. D'Angelo on Sequencing Therapies in Lymphoma

March 2nd 2021

Christopher R. D’Angelo, MD, discusses sequencing therapies for patients with lymphoma.

New Methods for MRD Testing Help to Predict Relapse Across Multiple Leukemia Subtypes

March 2nd 2021

Minimal residual disease has helped to predict relapse in numerous leukemia subtypes, with novel testing methods helping to identify the biomarker at a higher sensitivity than ever before.

BR Retains its Role in Frontline Waldenström Macroglobulinemia Despite the Utility of BTK Inhibitors

March 1st 2021

The treatment landscape of Waldenström macroglobulinemia is becoming increasingly complex with second-generation BTK inhibitors; however, the combination of bendamustine and rituximab remains the frontline standard of care for this patient population.

Martin Makes Sense of the Rapidly Evolving MCL Treatment Paradigm

March 1st 2021

As more options emerge in the mantle cell lymphoma paradigm, choosing among the agents available has become all the more challenging.

Immunotherapy Is on the Cusp of Major Breakthroughs in Multiple Myeloma

March 1st 2021

Immune therapy has evolved rapidly in multiple myeloma, and the field is on the verge of major improvements in outcomes.

A More Simplified Health Care System is Needed to Provide Value

March 1st 2021

Although scientific advances in hematology and oncology have been extraordinary, the US health care system faces significant challenges in ensuring that patients receive high-quality, cost-effective care.

Use of Omidubicel Therapy in Hematologic Malignancies

March 1st 2021

BMT CTN 1102 Study in High-Risk MDS

March 1st 2021

MRD Testing in R/R Follicular Lymphoma

March 1st 2021

Drs Caron A. Jacobson and Krish Patel comment on NGS (next-generation sequencing) and MRD (minimal residual disease) testing in relapsed/refractory follicular lymphoma.

Role of Rebiopsy in R/R Follicular Lymphoma

March 1st 2021

The rationale for rebiopsying patients who have relapsed/refractory follicular lymphoma and the types of molecular information that can be applied to treatment decisions.

DiNardo Describes Practical Considerations for the Management of Unfit Patients With AML

February 28th 2021

Several options have emerged for patients with acute myeloid leukemia who are not candidates to receive chemotherapy, with venetoclax-based regimens chief among them.